With the aim of protecting more and more Greek patients, a new product in Cardiovascular Medicine is launched. KERENDIA is now available for patients with CKD & Type 2 Diabetes. Welcome to Bayer Hellas internal Kerendia launch event, focusing on educating & preparing the Sales Team for a successful product promotion in the Greek market. In this event, you familiarized yourselves with the promotional materials & the role plays. This is the first POAP related to a pharmaceutical product. If you received this POAP, you are a True Pioneer in the Web3 space. Bayer is proudly promoting innovative practices. https://www.bayer.com/en/poap-tc

Thanks for for taking the time to complete this survey, It was a pleasure seeing you in Madrid!

I am heading the Data Assets and Insights Solutions team focusing on creating impact on our pipeline with FAIRified, enriched, semantically integrated data products (e.g., Hubble) in combination with solutions which provide insights to key scientific and business questions along the entire R&D value chain (e.g. Aelixir).

Thank you for connecting! This token shall commemorate our friendship! :)

Given the considerable amount of data that is collected throughout clinical trials, it can be asked if this data can be used to improve our understanding of the trial, regardless of outcome. The radiomics pilot seeks to provide a toolkit that is capable of analyzing the different modalities of information found in clinical trials (genome, gene expression, biomarker, clinical information, and imaging information) to derive insights into why a patient may be responding, or why a clinical trial was unsuccessful. The current efforts have focused on clinical trials in oncology, while collaborating with the RED-ONC function. Overall, the project is in its pilot state, and demonstrating a proof of concept, while documenting many challenges and learnings with the development of such a toolkit. Potential directions that could expand this toolbox include deriving the factors that best predict why a patient would stay in a clinical trial, and providing assistance with patient selection of clinical trials. Other potential directions involve suggesting why a particular trial may have been unsuccessful and providing that information back to the drug development team.

I studied piano performance and toxicology, and am now Master Data Manager at Bayer Pharma in the R&D Master Data Management team of Data Science & AI. I am passionate about team collaboration and rowing. Currently, I'm co-leading the IDMP Ontology, an international cross-industry project with 12 pharma companies for the unique identification of medicinal products to ensure patient safety. Talk to me about common standards and high quality data for better ML and AI outcomes, our next collaboration project, and/or our next jam session at the Bayer Berlin campus.